Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

250 Articles

Jon C. Ogg | Feb 1, 2012 at 3:43 PM EST

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Earnings season is still upon us. There are going to be many big earnings reports Thursday and we would consider…

Jon C. Ogg | Feb 1, 2012 at 8:18 AM EST

Top Analyst Upgrades & Downgrades (AMZN, ASH, BAC, C, CAT, DB, XOM, MWW, NEM, STX, SXC, WBSN, VRTX)

Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms…

Jon C. Ogg | Jan 31, 2012 at 11:34 AM EST

Another FDA Approval For Vertex (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has announced another FDA approval. While this approval will treat cystic fibrosis, the current total…

Jon C. Ogg | Jan 10, 2012 at 3:47 PM EST

Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of…

Jon C. Ogg | Jan 9, 2012 at 11:11 AM EST

Hepatitis-C to the Moon (BMY, INHX, ACHN, IDIX, VRTX)

You know how stocks sometimes react to news on peers… Today we are again seeing a run in the world…

Jon C. Ogg | Jan 4, 2012 at 8:01 AM EST

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at…

Jon C. Ogg | Dec 14, 2011 at 9:05 AM EST

Top Analyst Upgrades & Downgrades (MO, AVP, CE, LFC, EL, FITB, GE, MIND, VRTX, YHOO, YUM, GRPN)

Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday…

Jon C. Ogg | Nov 21, 2011 at 9:22 AM EST

Hepatitis C Makers Mostly Higher on Gilead/Pharmasset M&A (IDIX, INHX, VRTX)

The deal between Gilead and Phamasset is driving other hepatitis C developers higher this morning. Whether the 90% or so premium…

Jon C. Ogg | Nov 12, 2011 at 9:19 AM EST

24/7 Wall St. Top Analyst Calls of the Week (ALU, AMZN, AAPL, CSCO, CSC, CXW, DF, EPD, GNW, GMCR, GRPN, HD, MPEL, PIR, SRDX, TEVA, VRTX, YRCW, ALIM)

Each morning 24/7 Wall St. issues a summary list of key analyst upgrades, downgrades, and initiations issued by Wall Street…

Jon C. Ogg | Nov 10, 2011 at 8:35 AM EST

Top Analyst Upgrades & Downgrades (AAP, AMZN, BUD, CARB, CSCO, CSC, DF, EPD, HSP, KFT, LOGI, NOK, PCG, SD, SPRD, SRDX, VRTX)

These are some of Thursday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls. Advance Auto Parts.…

Jon C. Ogg | Nov 8, 2011 at 8:10 AM EST

Top Analyst Upgrades & Downgrades (AIXG, ALU, AZN, CXW, EMR, GSK, HON, HUM, KEX, MCHP, OVTI, PAA, RAX, STJ, TEVA, TRMB, VRTX, WFM)

These are some of Tuesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls. Aixtron SE (NASDAQ:…

Jon C. Ogg | Nov 7, 2011 at 10:04 AM EST

Vertex RA Study: When Good Is Not Good Enough (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) might have sounded as though shares would be up Monday morning if you were just…

Jon C. Ogg | Jul 14, 2011 at 8:34 AM EDT

Top Analyst Upgrades & Downgrades (ADTN, BMR, COF, CETV, ERTS, EPB, IDIX, LYG, MMM, NTGR, PLD, PL, SWC, TOL, TSM, VRTX, WSM)

Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Thursday…

Jon C. Ogg | Mar 8, 2011 at 8:12 AM EST

Top Analyst Upgrades & Downgrades (ANF, ALTR, AIG, APA, CIEN, EXPE, LAZ, LDK, MDC, NSM, NVDA, QCOM, URBN, VRTX)

Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Tuesday…

Jon C. Ogg | Feb 8, 2011 at 8:20 AM EST

Top Analyst Upgrades & Downgrades (AFL, ALKS, AMLN, GD, GNW, HGSI, IPI, MGM, SNDK, SHAW, VRTX)

These are some of this Tuesday’s top analyst calls with upgrades, downgrades, and initiations seen from Wall Street research firms.…

1 … 13 14 15 16 17

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Top Analyst Upgrades & Downgrades (AMZN, ASH, BAC, C, CAT, DB, XOM, MWW, NEM, STX, SXC, WBSN, VRTX)

Another FDA Approval For Vertex (VRTX)

Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)

Hepatitis-C to the Moon (BMY, INHX, ACHN, IDIX, VRTX)

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

Top Analyst Upgrades & Downgrades (MO, AVP, CE, LFC, EL, FITB, GE, MIND, VRTX, YHOO, YUM, GRPN)

Hepatitis C Makers Mostly Higher on Gilead/Pharmasset M&A (IDIX, INHX, VRTX)

24/7 Wall St. Top Analyst Calls of the Week (ALU, AMZN, AAPL, CSCO, CSC, CXW, DF, EPD, GNW, GMCR, GRPN, HD, MPEL, PIR, SRDX, TEVA, VRTX, YRCW, ALIM)

Top Analyst Upgrades & Downgrades (AAP, AMZN, BUD, CARB, CSCO, CSC, DF, EPD, HSP, KFT, LOGI, NOK, PCG, SD, SPRD, SRDX, VRTX)

Top Analyst Upgrades & Downgrades (AIXG, ALU, AZN, CXW, EMR, GSK, HON, HUM, KEX, MCHP, OVTI, PAA, RAX, STJ, TEVA, TRMB, VRTX, WFM)

Vertex RA Study: When Good Is Not Good Enough (VRTX)

Top Analyst Upgrades & Downgrades (ADTN, BMR, COF, CETV, ERTS, EPB, IDIX, LYG, MMM, NTGR, PLD, PL, SWC, TOL, TSM, VRTX, WSM)

Top Analyst Upgrades & Downgrades (ANF, ALTR, AIG, APA, CIEN, EXPE, LAZ, LDK, MDC, NSM, NVDA, QCOM, URBN, VRTX)

Top Analyst Upgrades & Downgrades (AFL, ALKS, AMLN, GD, GNW, HGSI, IPI, MGM, SNDK, SHAW, VRTX)

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Vertex Pharmaceuticals : VRTX

All Vertex Pharmaceuticals Articles

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Top Analyst Upgrades & Downgrades (AMZN, ASH, BAC, C, CAT, DB, XOM, MWW, NEM, STX, SXC, WBSN, VRTX)

Another FDA Approval For Vertex (VRTX)

Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)

Hepatitis-C to the Moon (BMY, INHX, ACHN, IDIX, VRTX)

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

Top Analyst Upgrades & Downgrades (MO, AVP, CE, LFC, EL, FITB, GE, MIND, VRTX, YHOO, YUM, GRPN)

Hepatitis C Makers Mostly Higher on Gilead/Pharmasset M&A (IDIX, INHX, VRTX)

24/7 Wall St. Top Analyst Calls of the Week (ALU, AMZN, AAPL, CSCO, CSC, CXW, DF, EPD, GNW, GMCR, GRPN, HD, MPEL, PIR, SRDX, TEVA, VRTX, YRCW, ALIM)

Top Analyst Upgrades & Downgrades (AAP, AMZN, BUD, CARB, CSCO, CSC, DF, EPD, HSP, KFT, LOGI, NOK, PCG, SD, SPRD, SRDX, VRTX)

Top Analyst Upgrades & Downgrades (AIXG, ALU, AZN, CXW, EMR, GSK, HON, HUM, KEX, MCHP, OVTI, PAA, RAX, STJ, TEVA, TRMB, VRTX, WFM)

Vertex RA Study: When Good Is Not Good Enough (VRTX)

Top Analyst Upgrades & Downgrades (ADTN, BMR, COF, CETV, ERTS, EPB, IDIX, LYG, MMM, NTGR, PLD, PL, SWC, TOL, TSM, VRTX, WSM)

Top Analyst Upgrades & Downgrades (ANF, ALTR, AIG, APA, CIEN, EXPE, LAZ, LDK, MDC, NSM, NVDA, QCOM, URBN, VRTX)

Top Analyst Upgrades & Downgrades (AFL, ALKS, AMLN, GD, GNW, HGSI, IPI, MGM, SNDK, SHAW, VRTX)

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026